Virus therapy takes on cervical and endometrial cancer
NCT ID NCT06552598
First seen Jan 27, 2026 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This study tests a modified virus (KD01) that targets and kills cancer cells, given alone or with an immunotherapy drug (AK104). It includes 97 women with cervical or endometrial cancer, some of whom have not responded to standard treatments. The goal is to see if the virus is safe and can shrink tumors, especially in younger women who want to preserve fertility.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KD01 (a modified virus that targets and kills cancer cells) combined with AK104 (an immunotherapy drug) and other agents
What this could lead to
If successful, this could offer a new treatment option for gynecologic cancers, potentially preserving fertility in younger women.
What could go wrong
This is an early Phase I/II trial with a small number of participants, so safety and effectiveness are not yet proven. The virus and immunotherapy may cause side effects or fail to shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.